Evaluation of efficacy of immunotherapy in children with asthma monosensitized to Alternaria

Turkish Journal of Pediatrics

Volumn 53, Issue 3, 2011, Pages 285-294

  Kiliç, Mehmet ^a   Altintaş, Derya Ufuk ^a   Yilmaz, Mustafa ^a   Bingöl Karakoç, Gülbin ^a   Burgut, Refik ^b   Güneşer Kendirli, Seval ^a  

^a Division of Pediatric Allergy and Immunology   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Alternaria; Asthma; Bronchial hyperresponsiveness; Children; Immunotherapy

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; FUNGUS ANTIGEN; IMMUNOGLOBULIN E;

ADOLESCENT; ALTERNARIA; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EOSINOPHIL COUNT; FUNGUS SPORE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; OPEN STUDY; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SENSITIZATION; SPUTUM LEVEL;

ADOLESCENT; ALLERGENS; ALTERNARIA; ASTHMA; BRONCHIAL PROVOCATION TESTS; CHILD; DESENSITIZATION, IMMUNOLOGIC; EOSINOPHIL CATIONIC PROTEIN; FEMALE; HUMANS; IMMUNOGLOBULIN E; MALE;

EID: 80053984274     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Corsico R, Cinti B, Feliziani V, et al. Prevalence of sensitization to Alternaria in allergic patients in Italy. Ann Allergy Asthma Immunol 1998; 80: 71-76.
2. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460-472.
3. Helbling A, Reimers A. Immunotherapy in fungal allergy. Curr Allergy Asthma Rep 2003; 3: 447-453.
4. Tabar AI, Lizaso MT, Garcia BE. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol 2008; 19: 67-75.
5. Lizaso MT, Tabar AI, García BE, et al. Double-blind, placebo-controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters. Pediatr Allergy Immunol 2008; 19: 76-81.
6. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119: 780-791.
7. Wahn U. Immunotherapy in children. Curr Opin Allergy Clin Immunol 2002; 2: 557-560.
8. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-178.
9. Bahçeciler NN, Işik U, Barlan BI, Başaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis. Pediatr Pulmonol 2001; 32: 49-55.
10. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE, Towsend M. Measuring quality of life in children with asthma. Qual Life Res 1996; 5: 35-46.
11. Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR, Math B. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998; 101: 163-170.
12. American Thoracic Society. Guidelines for methacholine and exercise challenge testing 1999. Am J Respir Crit Care Med 2000; 161: 309-320.
13. EAACI. Subcommittee on provocation tests with allergens. EAACI provocation tests with allergens. Allergy 1997; 52: 5-36.
14. Spanevello A, Confalonieri M, Sulotto F, et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med 2000; 162: 1172-1174.
15. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993; 147: 1126-1131.
16. Hirst JM. Changes in atmospheric spore content; diurnal periodicity and effects of weather. Trans Br Mycol Soc 1953; 36: 375-393.
17. Pajno GB, Morabito L, Barberio G. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo controlled study. Allergy 2000; 55: 842-849.
18. Alvarez MJ, Olaguibel JM, Garcia BE, Rodriquez A, Tabar AI, Urbiola E. Airway inflammation in asthma and perennial allergic rhinitis: relationship with nonspecific bronchial responsiveness and maximal airway narrowing. Allergy 2000; 55: 355-362.
19. Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006; 61: 191-197.
20. Goldstein G, Chai H. Efficacy of rush immunotherapy in decreasing bronchial sensitivity to inhaled antigens in perennial childhood asthma. Ann Allergy 1981; 47: 333-337.
21. Arvidsson MB, Löwhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59: 74-80.
22. Kandil AA, Hasan A, Taha O, El-Mesallamy H. Eosinophil cationic protein as a diagnostic marker for asthmatic children treated by immunotherapy. Egypt J Immunol 2003; 10: 67-76.
23. Ohashi Y, Nakai Y, Kakinoki Y, et al. Effect of immunotherapy on serum levels of eosinophil cationic protein in perennial allergic rhinitis. Ann Otol Rhinol Laryngol 1997; 106: 848-853.
24. Jakobsen CG, Bodiger U, Poulsen LK, Rogeen EL. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1, and G4 measured by surface plasmon resonance. Clin Exp Allergy 2005; 36: 193-198.
25. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. VI. IgE-mediated parameters during a one year placebo-controlled study of immunotherapy with Cladosporium. Allergy 1987; 42: 305-314.
26. Douglass JA, Thien FC, O'Hehir RE. Immunotherapy in asthma. Thorax 1997; 52: 522-529.
27. Lue K-H, Lin Y-H, Sun H-L, Lu K-H, Hsieh J-C, Chou M-C. Clinical and immunological effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17: 408-415.